Calgary, Alberta – TheNewswire - August 26, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has completed the one-week postoperative examination of the first patients who were implanted with the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”).  All patients are recovering well, and no complications have been observed.  With this important milestone achieved, a ...

"This is a moment our entire team has been working toward for years," said Dean Burns, CEO of Ocumetics. "Every milestone we've achieved in recent weeks reflects the dedication, expertise, and sheer determination of our people and partners. We're now just a few days away from transforming the future of vision correction with the first implantation of our groundbreaking accommodating intraocular lens. I couldn't be prouder of what our team has accomplished." Calgary, Alberta – TheNewswire - August 12, 2025 - ...

Calgary, Alberta – TheNewswire - July 30, 2025 - Ocumetics Technology Corp. ("Ocumetics" or the "Company") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that the ethics committee of the clinical site in Mexico City overseeing the first in-human study of the Ocumetics accommodating intraocular lens (the "Ocumetics Lens") has verbally approved the protocol for the study. Formal written approval is expected by August 5, 2025. Dean Burns, CEO of Ocume ...

公司突破性进展 - Ocumetics Technology Corp宣布在下一代人工晶状体技术研发中取得重大突破 成功在实验室测试中通过3D打印模制镜片在模拟睫状体压缩条件下展示调节能力变化 标志着恢复年轻视力研究的关键进展 [1] - 调节能力指眼睛在晶状体置换手术后远近焦距切换的自然功能 该技术旨在恢复因年龄增长丧失的自然对焦能力 [1] 技术验证与研发进展 - 测试使用公司自主研发的Lens Analyzer(IOLA)平台 通过模拟理论睫状体压力 证实模制镜片设计能产生符合人体试验要求的动态调节反应 [2] - 创始人兼首席科学官表示该成果验证了多年创新基础科学 实验室环境下可测量的调节能力使技术更接近重新定义视力恢复方式 [3] - 公司计划2025年夏季启动首次人体试验 目前处于临床前研究阶段 将持续与眼科研究人员 工程师及临床顾问协作推进严格研发路线 [3][5] 技术应用前景 - 开发中的眼内晶状体可植入自然晶状体腔室 通过眼部肌肉活动实现远近视距切换 有望使患者摆脱眼镜或隐形眼镜依赖 [5] - 该技术致力于提供传统视力矫正方案外的革命性选择 目标是通过先进晶状体技术提升患者生活质量并改变眼科领域格局 [4][5] 公司背景 - Ocumetics为加拿大研发型企业 专注于开发提升患者生活质量的视力矫正方案 在TSXV OTCQB及FRA交易所上市 [4] - 核心产品为创新型人工晶状体 现阶段主要推进临床前研究 首席执行官确认下一步将集中筹备人体试验 [2][5]